{{chembox
| ImageFile = Milacemide.svg
| ImageFile_Ref = {{chemboximage|correct|??}}
| ImageName = Skeletal formula of milacemide
| IUPACName = 2-(Pentylamino)acetamide<ref>{{cite web|title=milacemide - Compound Summary|url=https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53569&loc=ec_rcs|work=PubChem Compound|publisher=National Center for Biotechnology Information|accessdate=9 January 2012|location=USA|date=8 August 2005|at=Identifiers and Related Records}}</ref>

|Section1 = {{Chembox Identifiers
| CASNo = 76990-56-2
| CASNo_Ref = {{cascite|correct|??}}
| PubChem = 53569
| ChemSpiderID = 48376
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| UNII = 0HXT24RECU
| UNII_Ref = {{fdacite|correct|FDA}}
| MeSHName = milacemide
| ChEMBL = 75838
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| SMILES = CCCCCNCc(:[nH2]):[o]
| SMILES1 = CCCCCNCC(N)=O
| StdInChI = 1S/C7H16N2O/c1-2-3-4-5-9-6-7(8)10/h9H,2-6H2,1H3,(H2,8,10)
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GJNNXIYZWIZFRH-UHFFFAOYSA-N
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
}}

| Section2 = {{Chembox Properties
| C=7 | H=16 | N=2 | O=1 
| LogP = 0.754
}}

| Section3 = {{Chembox Related
| OtherCompounds = [[Tricine]]
}}
}}

'''Milacemide''' ([[International Nonproprietary Name|INN]])<ref>{{cite web|title=International Nonproprietary Names for Pharmaceutical Substances. Supplement to ''WHO Chronicle'', 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23|url=http://www.who.int/medicines/publications/druginformation/innlists/RL23.pdf|publisher=World Health Organization|accessdate=8 January 2016|page=6}}</ref> is an [[MAO-B]] inhibitor and [[glycine]] [[prodrug]].<ref name=Dysken>{{cite journal|last=Dysken|first=MW|author2=Mendels, J |author3=LeWitt, P |author4=Reisberg, B |author5=Pomara, N |author6=Wood, J |author7=Skare, S |author8=Fakouhi, JD |author9=Herting, RL  |title=Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.|journal=Journal of the American Geriatrics Society|date=May 1992|volume=40|issue=5|pages=503â€“6|pmid=1634705}}</ref> It has been studied for its effects on human memory and as a potential treatment for the symptoms of [[Alzheimer's disease]].<ref>{{cite book|last=Harris|first=Carol Turkington ; foreword by Joseph R.|title=The encyclopedia of the brain and brain disorders|year=2002|publisher=Facts on File|location=New York, NY|isbn=0-8160-4774-X|url=https://www.scribd.com/doc/10098801/The-Encyclopedia-of-the-Brain-and-Brain-Disorders|edition=2nd}}</ref> Early clinical trials did not show positive results however,<ref name=Dysken/> and the drug is now abandoned.

==References==
{{Reflist|2}}

{{Monoamine metabolism modulators}}
{{Glycine receptor modulators}}
{{Ionotropic glutamate receptor modulators}}

[[Category:Abandoned drugs]]
[[Category:Amino acid derivatives]]
[[Category:Monoamine oxidase inhibitors]]
[[Category:Glycine receptor agonists]]
[[Category:NMDA receptor agonists]]
[[Category:Prodrugs]]


{{nervous-system-drug-stub}}